Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress
Authors not listed
Immunotec Inc. · 2018
Abstract
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal forebrain, hippocampus, and the association cortices. Mild cognitive impairment (MCI) refers to individuals with cognitive impairment (often memory loss) that fails to meet clinical criteria for AD or another dementing illness.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-05-31 MST
Cite this
APA
Anonymous. (2018). Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress. <em>Immunotec Inc.</em>. https://clinicaltrials.gov/study/NCT03448055
Vancouver
Anonymous. Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress. Immunotec Inc.. 2018.
BibTeX
@misc{anon2018Nutrit,
title = {Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress},
author = {Anonymous},
journal = {Immunotec Inc.},
year = {2018},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
GlaxoSmithKline 2010
Open access · US-GOV
Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment
NVP Healthcare 2026
Open access · US-GOV
36-week, Single-center, Randomized, Double-blind, Parallel-design, Placebo-controlled Trial to Determine the Safety and Efficacy of NVP-NK4146 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Biomed Industries, Inc. 2018
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment
Novartis 2003
Open access · US-GOV
Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai 2019
Open access · US-GOV
Light, Metabolic Syndrome and Alzheimer's Disease: A Non-Pharmocological Approach
Journal of Alzheimer's disease : JAD 2026
Open access · OA